Hofseth BioCare ASA (Alesund, Norway), a Norwegian biotech company, has entered into a global innovation partnership with Catalent (Somerset, NJ) to develop a delayed formulation of Hofseth’s OmeGo fish oil made from sustainable, traceable and fresh Norwegian Atlantic salmon. Catalent will use its proprietary OptiGel DR technology to encapsulate OmeGo, enabling an enteric release profile for capsules with no additional external coating. Using a one-step manufacturing process, Hofseth avoids the heat and drying of the coating process, which can degrade the fish oil.
Hofseth is currently investigating the potential role of OmeGo fish oil in preventing the disease from getting worse and reducing inflammation, including inflammation caused by COVID-19. The results are expected in the coming months.
“Our research into the health benefits of our unique oil has come a long way in the past 18 months. We look forward to working with Catalent and hope to further expand the partnership and leverage innovative oral technologies to ensure the delivery system is effective, ”said Dr. Bomi Framroze, Hofseth Scientific Director. “OptiGel DR will enhance the OmeGo franchise, bring in advanced delivery technologies and raise its profile among the world’s leading healthcare companies.”
“This partnership is an exciting opportunity to combine the properties of a high quality ingredient with our new OptiGel DR capsule technology to create a product that provides optimal benefits and experiences for consumers,” said Aris Gennadios, PhD, President of Softgel and Oral Technologies at Catalent. “Our rich history and innovation in softgel technology has enabled us to develop a dosage form that delivers ingredients and formulations with an enteric release profile in robust capsules and with product performance that meets consumer expectations.”